Key Takeaways:
Akari Therapeutics Plc (Nasdaq: AKTX) announced positive preclinical data for its lead antibody-drug conjugate (ADC) candidate, AKTX-101, showing it works synergistically with KRAS inhibitors to kill pancreatic cancer cells. The findings, released in connection with the American Society of Clinical Oncology (ASCO) Annual Meeting, suggest a new strategy for tackling notoriously difficult-to-treat KRAS-mutated cancers.
"These data suggest that our PH1 RNA splicing modulator payload may offer a fundamentally differentiated mechanism capable of enhancing KRAS inhibitor activity," Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, said. He added that this represents an exciting opportunity for AKTX-101 and for RNA splicing modulation as a new therapeutic strategy across KRAS-driven tumors.
The study evaluated AKTX-101 in combination with adagrasib, an approved KRAS inhibitor, in pancreatic cancer models with KRAS G12D and G12C mutations. The combination demonstrated synergistic cell killing, an effect not seen with competing TROP2 ADCs that use traditional topoisomerase I inhibitor payloads. In contrast, those ADCs showed antagonism when paired with adagrasib, suggesting Akari's PH1 payload's unique mechanism is key to the synergy. The company recently secured approximately $5.5 million in a private placement to advance the program.
KRAS mutations are present in nearly half of colorectal cancers and are common in other solid tumors like pancreatic cancer, driving aggressive tumor growth. While KRAS inhibitors have marked a significant advance, tumors often develop resistance. Akari’s data suggests that its ADC, which targets the TROP2 receptor on cancer cells, can overcome this by using a novel payload, PH1, that modulates RNA splicing. This mechanism can degrade the pre-mRNA transcripts that carry cancer-driving mutations.
AKTX-101 is an antibody-drug conjugate, a class of therapy that uses an antibody to deliver a potent toxin directly to cancer cells. Akari's lead candidate uses a proprietary linker to carry its PH1 payload. Unlike conventional ADC payloads that damage DNA or microtubules, PH1 is designed to disrupt RNA splicing, a critical process for cell survival, while also activating the immune system. This differentiated approach has shown superior potency in preclinical models compared to other TROP2 ADCs in bladder, lung, and breast cancers.
The company is also developing AKTX-102, another ADC using the PH1 payload, which targets CEACAM5, a validated tumor antigen found across multiple solid tumors.
The positive data provides a boost for Akari, a clinical-stage biotech firm. The company has initiated IND-enabling studies for AKTX-101 and is targeting the start of a Phase 1 first-in-human clinical trial by mid-2027. The recent financing of $5.5 million, though modest, is intended to fund the company through this next critical step.
The financing includes the sale of American Depository Shares (ADSs) at $3.74 per share, along with various warrants. This cash injection provides Akari with runway through a key clinical milestone. For investors, the story is still early-stage and high-risk, but the unique mechanism of action and positive preclinical data in a notoriously difficult-to-treat cancer type offer a potential high-reward scenario. The key will be replicating these preclinical results in human trials.
This article is for informational purposes only and does not constitute investment advice.
